Tysabri's Next Steps Include Rheumatoid Arthritis, Crohn's Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
Elan/Biogen Idec may price the recently approved Tysabri at a premium to other multiple sclerosis therapies in anticipation of the additional indications. The price announcement could come within a few days.
You may also be interested in...
Biogen Idec/Elan's Tysabri Priced At Premium To Serono/Pfizer's Rebif
With a wholesale acquisition cost of $1,808, Tysabri will sell for at least a 20% premium to Rebif. Pricing for the MS therapy reflects the expectation of future indications in Crohn's and rheumatoid arthritis.
Biogen Idec/Elan's Tysabri Priced At Premium To Serono/Pfizer's Rebif
With a wholesale acquisition cost of $1,808, Tysabri will sell for at least a 20% premium to Rebif. Pricing for the MS therapy reflects the expectation of future indications in Crohn's and rheumatoid arthritis.
Antegren Brand Rejected Due To Possible Confusion With Ativan, Integrilin
Elan and Biogen Idec agreed to change the name of the multiple sclerosis monoclonal antibody natalizumab from Antegren to Tysabri after FDA expressed concern over potential drug name mix-ups